We have previously demonstrated that the stromal cell-derived factor (SDF-1)/CXCR4 system is involved in the metastasis of head and neck cancer. Additionally, it has been revealed that the blockade of CXCR4 by subcutaneous daily injection with AMD3100, a CXCR4 antagonist, may be effective in preventing metastasis in CXCR4-related head and neck cancer. Recent investigations have suggested that AMD070, a novel orally bioavailable inhibitor of CXCR4, may be minimally invasive compared with AMD3100. In the present study, we examined the effect of AMD070 on metastasis induced by the SDF-1/CXCR4 axis in B88-SDF-1 oral cancer cells, which express high levels of SDF-1 and CXCR4. Although treatment with AMD070 did not affect the anchorage-dependent growth of B88-SDF-1 cells, it significantly suppressed the anchorage-independent growth. Moreover, the SDF-1/CXCR4-dependent migration and invasion of B88-SDF-1 cells was significantly inhibited following treatment with AMD070. Subsequently, we performed an experimental therapy using AMD070 to prevent the distant metastasis of B88-SDF-1 cells in vivo. Daily oral administration of AMD070 significantly inhibited the lung metastasis of B88-SDF-1 cells in nude mice. These results indicated that AMD070 could be useful as a novel orally bioavailable inhibitor of oral cancer metastasis.
Introduction
We previously demonstrated that oral cancer cells expressing the chemokine receptor CXCR4 specifically metastasize to cervical lymph nodes via a gradient of stromal cell-derived factor-1 (SDF-1; also known as CXCL12) produced by the lymphatic stroma (1) (2) (3) (4) . Moreover, oral cancer cells that acquired an SDF-1/CXCR4 autocrine loop exhibited enhanced cell motility and contributed to lung metastasis (5) . Recent investigations have indicated that CXCR4 expression is involved in the metastatic potential of salivary gland cancer (6) . Furthermore, we have demonstrated that blocking CXCR4 with 1,1'-[1,4-phenylenebis(methylene)] bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride (AMD3100; also known as plerixafor), a CXCR4 antagonist, may have the potency to prevent metastasis in CXCR4-related head and neck cancer (5) (6) (7) . AMD3100 was first identified as a bicyclam derivative with potent activity against HIV infection (8) . However, AMD3100 is now clinically available for the mobilization of hematopoietic stem cells into the blood stream (9) . Although it is well known that the SDF-1/CXCR4 system contributes to both lymph node and distant metastasis in several types of cancer (10) (11) (12) (13) (14) (15) , many investigators have observed that AMD3100 also inhibits the invasion and metastasis of CXCR4-expressing cancer cells, both in vitro and in vivo (16) (17) (18) (19) . However, for the prevention of cancer metastasis, patients must receive a daily injection of AMD3100, as it has an estimated distribution half-life of 0.3 h and a terminal half-life of 5.3 h (9); therefore, this treatment places a burden on patients.
AMD070 (also called AMD11070) is a selective and orally bioavailable antagonist of CXCR4 with a half-life of 7.6-12.6 h (20, 21) . The mechanism by which AMD070 antagonizes CXCR4 has been determined to involve the formation of a hydrogen bond between the benzimidazole of AMD070 and the Tyr45 residue of CXCR4 (20, 21) . No apparent acute toxicity has been reported in oral bioavailability studies using AMD070 (20) . Despite the potential of AMD070 to contribute to cancer therapy, only two studies in acute lymphoblastic leukemia and pancreatic cancer have been performed to determine the efficacy of AMD070 as a cancer treatment in mice (22, 23) , and only one study has been performed using the oral administration route despite the high oral bioavailability of this drug (23 Merck kGaA, Darmstadt, Germany) supplemented with 10% fetal calf serum (FCS), 100 µg/ml streptomycin, and 100 u/ml penicillin in a humidified atmosphere of 95% air and 5% CO 2 at 37˚C.
Mice and the in vivo study. BALB/c nude mice were purchased from CLEA japan, Inc. (Osaka, japan). The mice were maintained under pathogen-free conditions. The experiments were initiated when the mice were 8 weeks of age and were performed as previously described (1, 5) . Briefly, the cells were inoculated into the blood vessels of nude mice (1x10 6 ). These mice were sacrificed at day 49. The presence or absence of distant metastases was confirmed by hematoxylin and eosin (H&E) staining. For experimental chemotherapy, the mice were treated by the daily oral administration of 0.2 ml of saline for a vehicle or the same volume of AMD070 (2 mg/kg; AdooQ BioScience LLC, Irvine, CA, uSA) according to the intraperitoneal administration in vivo described by Morimoto et al (23) .
MTT assay. Cells were seeded on a 96-well plate (Falcon; BD Biosciences, Franklin Lakes, Nj, uSA) at 5x10 3 cells/well in DMEM containing 10% FCS. Twenty-four hours later, the cells were treated with or without 2 µM AMD3100 (Sigma-Aldrich: Merck kGaA) or 6.6 µM AMD070. After 24 or 48 h, the number of cells was quantified by an assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich: Merck kGaA).
Soft agar assay. B88 cells were seeded at a density of 1x10 5 cells/well in 6-well plates in 2 ml of 0.6% agar (Wako Pure Chemical Industries, Ltd., Osaka, japan) supplemented with DMEM in the presence of 10% FCS. Twenty-four hours later, the cells were treated with or without 6.6 µM AMD070. After 14 and 21 days, the colonies containing >20 cells were counted.
Wound healing assay. After 24 h of culture, a linear wound was generated by scraping some confluent monolayers of cells with a 200-µl pipet tip in the presence of either 2 µM AMD3100 or 6.6 µM AMD070. unattached cells were washed off with agitation. Cells were imaged by a digital camera (DP21; Olympus Corp., Tokyo, japan) at the same grid location after 48 h. Each line was plated and wounded in triplicate.
In vitro cell migration and invasion assays. The in vitro migration and invasion of B88 cells were evaluated using Transwells (Corning, Inc., Corning, NY, uSA) and a BioCoat™ Matrigel™ Invasion Chamber with BD Matrigel Matrix (Falcon; BD Biosciences), respectively, as previously described (18) . Briefly, 5x10 4 cells were seeded on polycarbonate filters of 8 µm pore size in a Transwell migration assay, and 5x10 5 cells were seeded on Matrigel-coated polycarbonate filters of 8 µm pore size in a Matrigel invasion assay both in DMEM containing 10% FCS in the upper and lower chambers. After 48 h of culture, the cells and Matrigel on the upper-surface of the membrane were wiped out with a cotton swab in both assays, and the membrane was removed from the chamber, and stained with H&E at room temperature. After enclosure of the membrane into cover glass, plugged cells in pores and cells that attached to the underside of the membrane were counted in 10 fields at a high-power view (magnification, x400) with a BX53 upright microscope (Olympus Corp.) by a third person blinded to treatment conditions. In some experiments, 2 µM AMD3100 or 6.6 µM AMD070 were co-incubated with cells seeded in the upper chamber. All of the assays were performed in triplicate.
Statistical analysis. Statistical differences between the means among groups were evaluated with StatView 4.5 (Abacus Concepts, Berkeley, CA, uSA) using one-way analysis of variance (ANOVA), with the level of significance at P<0.05. The significance level was set at 5% for each analysis.
Results
Effect of AMD070 on cell growth. We previously demonstrated that AMD3100, a CXCR4 inhibitor, did not affect the anchorage-dependent growth of B88-mock or B88-SDF-1 cells, but did inhibit the anchorage-independent growth of the B88-SDF-1 cells (5). We compared the effect of AMD070 with AMD3100 on the growth of B88-SDF-1 cells. Neither inhibitor affected the anchorage-dependent growth of the B88-mock or B88-SDF-1 cells (Fig. 1) . Additionally, AMD070 did not induce any cytotoxicity in the CAL-27 oral cancer cells lacking CXCR4 expression, which were treated at the same concentration (data not shown). Conversely, AMD070 significantly suppressed the anchorage-dependent growth of the B88-SDF-1 cells ( Fig. 2A and B) .
Effect of AMD070 on SDF-1/CXCR4-dependent cell migration and invasion. We next investigated the effect of AMD070 on the SDF-1/CXCR4-dependent migration and invasion of cells. Wound healing assays revealed that the enhanced motility of B88-SDF-1 cells was significantly impaired by treatment with AMD3100 and AMD070 (Fig. 3A and B) . AMD070 also significantly inhibited the migration and Matrigel invasion of B88-SDF-1 cells, as demonstrated by the Transwell chamber assays, similar to the effect of treatment with AMD3100 ( Fig. 3C and D) .
Effect of AMD070 on the lung metastasis of B88-SDF-1 cells.
Next, we performed intravenous inoculation of B88-SDF-1 cells with acquired metastatic potential to the lungs (5). Metastatic nodules in the lungs were histopathologically detected in 5/9 of the control mice, but were only detected in 2/10 of the mice treated with AMD070 (Fig. 4A) . Moreover, a significant reduction in the number of metastatic lung nodules was observed in the mice treated with AMD070 when compared with the control (16 vs. 3), during a 7-week observation period. We also confirmed the presence of metastatic cancer cells in extracted lung tissues using a quantitative Alu-PCR assay. Consequently, the expression of human Alu DNA in mice treated with AMD070 was significantly lower than in mice treated with saline (Fig. 4B) . Furthermore, during the 49-day observation, AMD070 treatment did not induce body weight loss despite the tumor bearing-condition of the mice (control, 11.1±17.5% loss; AMD070, 0.9±14.5% loss), indicating that there is less toxicity associated with the daily oral administration of AMD070 (data not shown). In addition, we did not detect the apparent macroscopic organ abnormalities associated with the daily oral administration of AMD070.
Discussion
In the present study, we investigated the effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cell lines in vitro and in vivo. The findings obtained from the present series of experiments are as follows. Firstly, AMD070 did not affect anchorage-dependent cell growth, but significantly suppressed anchorage-independent growth of B88-SDF-1 cells. Secondly, AMD070 significantly inhibited the migration and Matrigel invasion of the cells. Thirdly, oral administration of AMD070 significantly inhibited lung metastasis of the cells in nude mice. These results indicated that AMD070 may represent a novel orally bioavailable inhibitor for the metastases of oral cancer.
The chemokine receptor CXCR4 and its cognate ligand SDF-1 have been implicated in B-cell lymphopoiesis, bone marrow myelopoiesis, vascular development, cardiogenesis and HIV infection (24) (25) (26) (27) . More recently, the SDF-1/CXCR4 system has been demonstrated to determine the destination of various tumor cells, including breast, ovarian, prostate and kidney cancer, brain tumor, lung and thyroid cancer, neuroblastoma and malignant melanoma cells (10) (11) (12) (13) (14) (15) (28) (29) (30) . Due to its classification as a cell surface G protein-coupled receptor, CXCR4 has been investigated for its potential as a therapeutic target for these diseases, particularly for the treatment of HIV (27) . While several new compounds that act against CXCR4 are under preclinical development (31), the only currently clinically available inhibitor of CXCR4 is AMD3100 (plerixafor or Mozobil), which is used for hematopoietic stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma (9) . Although we, and numerous other investigators, have demonstrated the efficacy of CXCR4 inhibition in the prevention of cancer metastasis (5) (6) (7) 18, 31) , the pharmacokinetics of AMD3100 deem it unsuitable for use via oral administration due to the large size and cationic nature of the compound (32) .
AMD070 was initially developed as an orally bioavailable antagonist of CXCR4, capable of suppressing the replication of X4 (T-tropic) HIV-1 and the interaction of gp120/CXCR4 (20, 21) . AMD070 has been characterized as an allosteric inhibitor, which involves the formation of a hydrogen bond between the benzimidazole of AMD070 and the Tyr45 residue of CXCR4; the IC 50 value of AMD070 was also determined to be 13 nM (33) . In the present study, we used AMD070 at a concentration of 6.6 µM, according to the results of a previous study (34) , and no cytotoxicity was recorded in the oral cancer cells with or without CXCR4 expression. Moreover, the effect of AMD070 on the migration and invasion of the cells was similar to that of ADM3100. In a previous clinical trial, AMD070 was able to achieve plasma concentrations of 6.6 mM with an oral administration dose of 400 mg in fasted healthy volunteers (20) . It was also demonstrated that leukocytosis followed AMD070 dosing in all subjects, ranging from 1.3 to 2.9-fold above the baseline, and peaking at 2-4 h following administration (20) . Therefore, as effective CXCR4-related therapies may require daily administration of CXCR4 antagonists to continuously prevent the migration of pre-metastatic cells to metastatic sites, this may lead to chronic leukocytosis. In our prior study, the daily administration of AMD3100 to immunocompetent mice induced transient leukocytosis after 1 day (control, 5,100/µl vs. AMD3100, 8,030/µl); however, the number of leukocytes in mice treated with AMD3100 gradually decreased, almost to the baseline (unpublished data). Thus, leukocytosis following treatment with AMD070 may be negligible, although we have no data regarding leukocyte changes in mice following treatment with AMD070 in the present study.
In the present study, AMD070 treatment induced no apparent body weight loss during the 49-day observation period. Additionally, we have previously reported that mice inoculated with CXCR4-knockdown cells were significantly heavier than mice inoculated with control cells, and that the production of the cachexia-induced cytokine interleukin (IL)-6 was impaired in these CXCR4-knockdown cells both in vitro and in vivo (7) . A number of investigators have reported the importance of IL-6 in cancer cachexia and anorexia in various types of cancer (35) . Thus, our data indicated that the blockade of CXCR4 by AMD070 treatment may also inhibit cancer cachexia via the suppression of IL-6 production in CXCR4-related oral cancer. Several investigators have demonstrated the possible efficacy of AMD070 in the treatment of high-grade malignant tumors (23, 34) . For example, O'Boyle et al demonstrated that AMD070 abrogated melanoma cell migration towards liver-resident myofibroblasts excreting CXCL12, and that it was significantly more effective than AMD3100 (34) . Moreover, Morimoto et al determined that treatment with AMD070 could overcome gemcitabine resistance in pancreatic cancer cells (23) . In clinical trials, Stone et al demonstrated that no apparent acute toxicity was present in oral bioavailability studies using AMD070 (20) , suggesting that CXCR4 is a safe therapeutic target. In addition, more recent investigations have identified several candidate inhibitors of CXCR4 in CXCL12 competition binding studies (36) . Although AMD3100 is the only currently clinically available inhibitor, these new compounds, including AMD070, may have the potential to become novel candidates for CXCR4-targeting therapies.
